Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

SNMMI 2013 Image of the Year: Radium-223 Dichloride Response in Bone Metastases in Breast Cancer Patients

An 18F-FDG positron emission tomography/computed tomography (PET/CT) scan illustrating the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease has been selected as the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 Image of the Year. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNMMI’s 2013 Annual Meeting in Vancouver, British Columbia, Canada.

SNMMI 2013 Image of the Year: Radium-223 Dichloride Response in Bone Metastases in Breast Cancer Patients

Vancouver, British Columbia – An 18F-FDG positron emission tomography/computed tomography (PET/CT) scan illustrating the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease has been selected as the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 Image of the Year. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNMMI’s 2013 Annual Meeting in Vancouver, British Columbia, Canada.

Sequester bites NIH funding, Alzheimer’s research

With increasing prevalence of Alzheimer’s disease threatening to bankrupt Medicare and Medicaid by 2050, the fiscal pinch of the sequester could extend decades into the future and compromise already-limited progress on Alzheimer’s disease prevention and treatment. A letter in the New York Times detailed the data.

SNMMI: Cardiac PET/MR on par with PET/CT

MR can be employed for PET attenuation correction, and PET/MR assessment for cardiac muscle viability delivered comparable results to PET acquired using PET/CT, according to research presented at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver.

Siemens Introduces Continuous FlowMotion PET•CT

At the 2013 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 8-12 in Vancouver, B.C., Canada, Siemens Healthcare (booth 720) will introduce Biograph mCT Flow – a groundbreaking new positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

IBA Molecular, MIM Software Sign Agreement for PETLinQ Enhancement

IBA Molecular North America, Inc. (IBA Molecular) and MIM Software Inc. (MIM Software™) have announced an agreement to co-develop enhancements to the IBA Molecular PETLinQ™ suite of products

SNMMI: PET/MR surpasses PET/CT gold standard for recurrent prostate cancer

PET/MR scans demonstrated a higher capacity for mapping recurrent prostate cancer by finding more areas of prostate cancer metastases than hybrid PET/CT imaging, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting in Vancouver.

SNMMI: Alzheimer’s precursor? Amyloid connected to hypometabolism in healthy brains

Amyloid plaque burden has been linked with hypometabolism of neurons in areas of the brain associated with Alzheimer’s disease, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver.